Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Open access
Spaepen, Karoline, Stroobants, Sigrid, Dupont, Patrick, Thomas, José, Vandenberghe, Peter, Balzarini, Jan, De Wolf‐Peeters, Christine, Mortelmans, Luc, Verhoef, Gregor·2001·British Journal of Haematology

Abstract

To assess the ability of restaging positron emission tomography (PET) scanning to predict clinical outcome after first‐line treatment in patients with Hodgkin's disease, we included 60 patients with histologically proven HD, who underwent whole‐body [18 F]‐fluorodeoxygenase ([18 F]‐FDG)‐PET studies after first‐line treatment and with a follow‐up of at least 1 year. Persistence or absence of residual disease on PET was related to progression‐free survival (PFS) using Kaplan–Meier survival analysis. After treatment, 55 patients showed a normal [18 F]‐FDG‐PET scan; 50 of 55 remained in complete remission (CR), with a median follow‐up of 955 d. Only five patients relapsed (median PFS, 296 d). During follow‐up in all five patients, [18 F]‐FDG‐PET was the first tool that became positive for relapse. Persistent abnormal [18 F]‐FDG uptake was seen in only five patients; all of them relapsed (median PFS, 296 d). In four of five patients, only PET predicted persistent disease. All relapses were proven histologically. Two‐year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [18 F]‐FDG‐PET has an important prognostic role in the post‐treatment evaluation of HD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2001.03169.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 169

Metadata

Authors
Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P., Balzarini, J., De Wolf‐Peeters, C., Mortelmans, L., & Verhoef, G.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2001-11
Volume
115
Issue
2
Pages
272-278
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2056246696
Cited by
169
References
1
FWCI
6.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? https://app.cochat.ai/papers/10.1046/j.1365-2141.2001.03169.x
The paper
Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P., Balzarini, J., De Wolf‐Peeters, C., Mortelmans, L., & Verhoef, G. (2001). Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2001.03169.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.